# Nivolumab, Ipilimumab, and Short-course Radiotherapy in Adults With Newly Diagnosed, MGMT Unmethylated Glioblastoma

> **NCT03367715** · PHASE2 · COMPLETED · sponsor: **NYU Langone Health** · enrollment: 10 (actual)

## Conditions studied

- MGMT-unmethylated Glioblastoma (GBM)
- GBM

## Interventions

- **DRUG:** Nivolumab
- **DRUG:** Ipilimumab
- **RADIATION:** Radiation Therapy (RT)

## Key facts

- **NCT ID:** NCT03367715
- **Lead sponsor:** NYU Langone Health
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-02-07
- **Primary completion:** 2021-05-20
- **Final completion:** 2022-03-17
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2022-07-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03367715

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03367715, "Nivolumab, Ipilimumab, and Short-course Radiotherapy in Adults With Newly Diagnosed, MGMT Unmethylated Glioblastoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03367715. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*